A new treatment for ischemic stroke

Read More

Our Goal

Ischemic stroke is the second leading cause of death and a major cause of disability. Avilex Pharma investigates a novel principle in treatment to meet this major medical need.


Avilex Pharma develops novel inhibitors of PDZ domain proteins to target a range of unmet medical needs. Our lead candidate UCCB01-144 is a drug candidate for the treatment of ischemic stroke.

Read More

The Company

Avilex Pharma is a spin out from the University of Copenhagen, founded by Professor Kristian Strømgaard and Ass. Prof. Anders Bach of the Department of Drug Design and Pharmacology.

Read More

Latest News

Avilex Pharma receives Wellcome Trust Translation Award to advance their ischemic stroke program and raises in total 28 milllion DKK (3.75 million Euro).

Read More
© Copyright 2016 Avilex Pharma. All rights reserved.
Avilex Pharma, Ole Maaløes Vej 3, 2200 Copenhagen, DK